TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
|
|
- Damon Matthews
- 6 years ago
- Views:
Transcription
1 TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
2 CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the real future?
3 Overactive bladder (OAB)
4 OVERLAP BETWEEN OAB
5 TYPE OF OAB OAB Dry +
6 TREATMENT OF OVERACTIVE BLADDER IN ADULTS AUA/SUFU Guideline (2012); Amended (2014) Diagnosis & Treatment Algorithm: AUA/SUFU Guideline on Non-Neurogenic Overactive Bladder in Adults History and Physical; Urinalysis Diagnosis unclear or additional information needed Consider urine culture, post-void residual, bladder diary, and/or symptom questionnaires Not OAB or Complicated OAB; treat or refer Signs/symptoms of OAB, (-) urine microscopy Signs/symptoms of OAB Patient education: - Normal urinary tract function - Benefits/risks of treatment alternatives - Agree on treatment goals Patient desires treatment, is willing to engage in treatment, and/or treatment is in patient s best interests Follow-up for efficacy and adverse events Behavioral Treatments Standard (consider adding pharmacologic management if partially effective) Treatment goals not met after appropriate duration*; Patient desires further treatment, is willing to engage in treatment, and/or further treatment in patient s best interests Treatment goals met In extremely rare cases, consider urinary diversion or augmentation cystoplasty Pharmacologic management Standard With active management of adverse events; consider dose modification or alternate medication if initial treatment is effective but adverse events or other considerations preclude continuation Treatment goals not met after appropriate duration*; Patient desires further treatment, is willing to engage in treatment, and/or further treatment in patient s best interests Reassess and/or refer; consider urine culture, post-void residual, bladder diary, symptom questionnaires, other diagnostic procedures as necessary for differentiation Signs/symptoms consistent with OAB diagnosis; Treatment goals not met after appropriate duration*; Patient desires further treatment, is willing to engage in treatment, and/or further treatment in patient s best interests Consider in carefully-selected and thoroughly-counseled patients with moderate to severe symptoms Intradetrusor onabotulinumtoxina Standard (patients must be willing to perform CISC) OR Peripheral tibial nerve stimulation (PTNS) Recommendation (patients must be willing and able to make frequent office visits) OR Sacral neuromodulation (SNS) Recommendation The complete OAB Guideline is available at Copyright 2014 American Urological Association Education and Research, Inc. *Appropriate duration is 8 to 12 weeks for behavioral therapies and 4 to 8 weeks for pharmacologic therapies
7 DIAGNOSIS OF OAB The clinician should engage in a diagnostic process to document symptoms and signs that characterize OAB and exclude other disorders that could be the cause of the patient s symptoms; the minimum requirements for this process are a careful history, physical exam, and urinalysis. OAB is not a disease; it is a symptom complex that generally is not a life-threatening condition. After assessment has been performed to exclude conditions requiring treatment and counseling, no treatment is an acceptable choice made by some patients and caregivers. Clinicians should provide education to patients regarding normal lower urinary tract function, what is known about OAB, the benefits vs. risks/burdens of the available treatment alternatives and the fact that acceptable symptom control may require trials of multiple therapeutic options before it is achieved.
8 Treatment of OAB
9 TREATMENT OF OAB First-Line Treatments: 1. Clinicians should offer behavioral therapies (e.g., bladder training, bladder control strategies, pelvic floor muscle training, fluid management) as first line therapy to all patients with OAB. 2. Behavioral therapies may be combined with pharmacologic management.
10 TREATMENT OF OAB Second-Line Treatments: 1. Clinicians should offer oral anti-muscarinics or oral ß3-adrenoceptor agonists as second-line therapy. 2. If an immediate release (IR) and an extended release (ER) formulation are available, then ER formulations should preferentially be prescribed over IR formulations because of lower rates of dry mouth. 3. Transdermal (TDS) oxybutynin (patch [now available to women ages 18 years and older without a prescription] or gel) may be offered.
11 TREATMENT OF OAB Second-Line Treatments: 4. If a patient experiences inadequate symptom control and/or unacceptable adverse drug events with one anti-muscarinic medication, then a dose modification or a different anti-muscarinic medication or b3-adrenoceptor agonist may be tried. 5. Clinicians should not use anti-muscarinics in patients with narrow angle glaucoma unless approved by the treating ophthalmologist and should use anti-muscarinics with extreme caution in patients with impaired gastric emptying or a history of urinary retention.
12 TREATMENT OF OAB Second-Line Treatments: 6. Clinicians should manage constipation and dry mouth before abandoning effective anti-muscarinic therapy. Management may include bowel management, fluid management, dose modification or alternative anti-muscarinics. 7. Clinicians must use caution in prescribing anti-muscarinics in patients who are using other medications with anti-cholinergic properties. 8. Clinicians should use caution in prescribing anti-muscarinics or ß3- adrenoceptor agonists in the frail OAB patient. 9. Patients who are refractory to behavioral and pharmacologic therapy should be evaluated by an appropriate specialist if they desire additional therapy.
13 TREATMENT OF OAB Third-Line Treatments: 1. Specialists may offer intradetrusor onabotulinumtoxina (100U) as third-line treatment in the carefully-selected and thoroughlycounseled patient who has been refractory to first- and second-line OAB treatments. The patient must be able and willing to return for frequent post-void residual evaluation and able and willing to perform self-catheterization if necessary. 2. Specialists may offer peripheral tibial nerve stimulation (PTNS) as third line treatment in a carefully selected patient population.
14 TREATMENT OF OAB Third-Line Treatments: 3. Specialists may offer sacral neuromodulation (SNS) as third-line treatment in a carefully-selected patient population characterized by severe refractory OAB symptoms or patients who are not candidates for second-line therapy and are willing to undergo a surgical procedure. 4. Practitioners and patients should persist with new treatments for an adequate trial in order to determine whether the therapy is efficacious and tolerable.
15 TREATMENT OF OAB Additional Treatments: 1. Indwelling catheters (including transurethral, suprapubic, etc.) are not recommended as a management strategy for OAB because of the adverse risk/benefit balance except as a last resort in selected patients. 2. In rare cases, augmentation cystoplasty or urinary diversion for severe, refractory, complicated OAB patients may be considered.
16 TREATMENT OF OAB Treatments follow-up: Combination therapeutic approaches should be assembled methodically, with the addition of new therapies occurring only when the relative efficacy of the preceding therapy is known. Therapies that do not demonstrate efficacy after an adequate trial should be ceased. The clinician should offer follow up with the patient to assess compliance, efficacy, side effects, and possible alternative treatments.
17 PERSISTENCE WITH ANTIMUSCARINICS CAN BE A CHALLENGE Solifenacin (n=1,381) Tolterodine ER (n=1,758) Tolterodine IR (n=482) Oxybutynin ER (n=590) Oxybutynin IR (n=1371) Propiverine (n=97) Trospium (n=352) Darifenacin (n=23) Flavoxate (n=89) Patients (%) Months ER, extended release; IR, immediate release Adapted from Wagg et al. BJU Int 2012;110(11):
18 Beta-3 adrenoceptor agonist (Betmiga ) - Panacea?
19 BETMIGA MODE OF ACTION Nerve pathways in normal bladder control Mode of action of OAB treatments Adapted from Chu FM, Dmochowski R. Am J Med 2006;119(3 Suppl 1):3 8.
20 Beta-3 adrenoceptor agonist BETMIGA PHASE 3 CLINICAL TRIAL PROGRAMME
21 CO-PRIMARY ENDPOINTS 24 (FAS-I) 24 (FAS) FAS, Full Analysis Set FAS-I, FAS Incontinence *Statistically significantly superior compared with placebo at the 0.05 level with multiplicity adjustments Adapted from Khullar V, et al. Eur Urol 2013;63(2):
22 CO-PRIMARY ENDPOINTS Mean change from baseline in mean number of incontinence episodes per 24 hrs Baseline Week 4 Week 8 Week * * Placebo Mirabegron 50 mg Mirabegron 100 mg Tolterodine ER 4 mg (n = 291) (n = 293) (n = 300) NS * NS * FAS Incontinence Set NS, No statistically significant improvement versus placebo *Statistically significantly superior compared with placebo at the 0.05 level with multiplicity adjustments Adapted from Khullar V, et al. Eur Urol 2013;63(2):
23 CO-PRIMARY ENDPOINTS Mean change from baseline in mean number of micturitions per 24 hrs Baseline Week 4 Week 8 Week * * NS NS * * Placebo Mirabegron 50 mg Mirabegron 100 mg Tolterodine ER 4 mg (n=480) (n=473) (n=475) FAS Full Ananlysis Set NS, No statistically significant improvement versus placebo *Statistically significantly superior compared with placebo at the 0.05 level with multiplicity adjustments Adapted from Khullar V, et al. Eur Urol 2013;63(2):
24 CO-PRIMARY ENDPOINTS 24 (FAS-I) 24 (FAS) FAS, Full Analysis Set FAS-I, FAS Incontinence *Statistically significantly superior compared with placebo at the 0.05 level with multiplicity adjustments Adapted from Herschorn S, et al. Urology Aug;82(2):
25 MIRABEGRON SIGNIFICANTLY IMPROVED SYMPTOM BOTHER (OAB-Q) AT EACH VISIT (FAS) Improvement Mean change from baseline to final visit in symptom bother * * * * * Baseline Week 4 Week 8 Week 12 Final Visit Placebo Mirabegron 50 mg Tolterodine ER 4 mg * * * (n=475) (n=465) (n=469) FAS, Full Analysis Set OAB-q, overactive bladder questionnaire 1. Adapted from Khullar V, et al. Eur Urol 2013;63(2): * Statistically significant improvement versus placebo at 0.05 level
26 MIRABEGRON SIGNIFICANTLY IMPROVED TREATMENT SATISFACTION AT FINAL VISIT Improvement Mean change from baseline to final visit in TS-VAS Placebo (n=428) Mirabegron 50 mg (n=414) * Tolterodine ER 4 mg (n=425) * * Statistically significant improvement versus placebo at 0.05 level FAS, Full Analysis Set; TS-VAS, Treatment Satisfaction Visual Analog Scale 1. Adapted from Khullar V, et al. Eur Urol 2013;63(2):
27 MIRABEGRON SIGNIFICANTLY IMPROVED TOTAL HRQOL SCORE AT FINAL VISIT COMPARED WITH PLACEBO Improvement Mean change from baseline to final visit in total HRQoL * * 0 Baseline Week 4 Week 8 Week 12 Final Visit Placebo Mirabegron 50 mg Tolterodine ER 4 mg (n = 428) (n = 414) (n = 425) * Statistically significant improvement versus placebo at 0.05 level *Data are least squares mean adjusted for baseline, gender and geographical region; Statistically significantly superior compared with placebo at the 0.05 level; HRQoL=health-related quality of life; OAB-q=Overactive Bladder Questionnaire; FAS=full analysis set 1. Adapted from Khullar V, et al. Eur Urol 2013;63(2):
28 Mean change from baseline to final visit in micturitions per 24 hrs Pre-specified subgroup analysis by prior OAB therapy Pooled data ISE (046/047/074): micturition frequency (FAS) (n=704) FAS, Full Analysis Set ISE, Integrated Summary of Effectiveness OAB Baseline (CI -1.01, -0.47) Placebo (n=688) (n=624) Mirabegron 50 mg 1. Adapted from Nitti VW, et al. Int J Clin Pract Jul;67(7): OAB (CI -0.62, -0.05) (n=636) OAB
29 Post-hoc subgroup analysis : Previous OAB therapy discontinued due to insufficient efficacy: micturitions (FAS) Mean change from baseline to final visit in micturitions per 24 hrs Baseline FAS, Full Analysis Set Placebo Mirabegron 50 mg Tolterodine ER 4 mg (n=159) (CI -1.15, -0.04) (n=160) Adapted from Khullar et al. BMC Urology 2013, 13: (CI -0.64, 0.47) OAB (n=155) -1.11
30 Once daily mirabegron in a 50 or 100 mg dose is an effective treatment for overactive bladder symptoms with a low occurrence of side effects. Nitti VW, et al. Results of a randomized phase III trial of Mirabegron in patients with overactive bladder. J Urol. 2013;189(4):
31 The evidence described would suggest that mirabegron is not a cure for OAB, but is as efficacious as most antimuscarinics including tolterodine ER 4 mg compared with placebo regarding: objective measures such as reduction in number of voids per 24 hours, mean volume per void, mean number of episodes of general urinary incontinence, urgency urinary incontinence and urgency per 24 hours. subjective measures such as severity of urgency, PPBC, ICIQ-OAB and KHQ. It is important to note however that urgency, the pathognomonic symptom of OAB, was never the primary outcome measure. With regard to tolerability, the data would suggest that patients taking mirabegron suffer a similar rate of TEAEs as those taking placebo alone, whereas the rate in those on antimuscarinics is greater.
32 Mirabegron, the first and only licensed β3-ar agonist for the treatment of OAB, offers an efficacious and safe alternative to first-line treatment in adult patients poorly controlled with or intolerant to antimuscarinics. Future studies are required to provide more information regarding potential benefits of combined therapy with antimuscarinics or α-blockers and also longer term effects of β3- AR agonists.
33 LASER treatment on OAB WET - a flash in the pan or the real future?
34 This clinical evaluation of a new non-invasive Er:YAG laser treatment for stress and mixed urinary incontinence showed high efficacy in improvement of UI with no adverse effects noted. Patients discomfort during the treatment was minimal and satisfaction very high. For evaluation of the duration of the treatment effects, longer follow-ups are necessary and we are looking forward to seeing our patients at 12 and 24 months postop.
35 We included 175 women (aged 49.7 ± 10 years) with newly diagnosed SUI (66% of women) and MUI (34%), respectively. Patients were clinically examined and classified by incontinence types (SUI and MUI) and grades (mild, moderate, severe, and very severe) using International Consultation on Incontinence Modular Questionnaire (ICIQ) and assessing Incontinence Severity Index (ISI). The results of our study, have shown that new non-invasive Er:YAG laser could be regarded as a promising additional treatment strategy for SUI with at least one year lasting positive effects. On the other hand, it does not seem appropriate for treating MUI.
36 CLINICAL EXPERIENCE LASER or HIFU Efficacy and effect and cost single or combination therapy specialist and certificate
37 TAKE HOME MESSAGE Overactive bladder (OAB) -precise diagnosis Treatment of OAB -combination therapies Beta-3 adrenoceptor agonist (Betmiga ) - may first-line medication but no panacea LASER treatment - the real changing future
38 THANK YOU FOR PAYING ATTENTION!
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationOveractive Bladder beyond antimuscarinics
Overactive Bladder beyond antimuscarinics Marcus Drake Bristol Urological Institute Conflicts of interest; Allergan, AMS, Astellas, Ferring, Pfizer Getting the diagnosis right Improving treatment Improving
More informationUrinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives
Urinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives Arun Sahai PhD, FRCS (Urol) Consultant Urological Surgeon & Honorary Senior Lecturer Guy s Hospital
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More informationUrogynecology Office. Can You Hold? An Update on the Treatment of OAB. Can You Hold? Urogynecology Office
Urogynecology Office Urogynecology Office Can You Hold? An Update on the Treatment of OAB Can You Hold? Karen Noblett, MD Professor and Chair Department of OB/GYN University of California, Riverside Disclosures
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationDiagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline. IDENTITY Citation Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr,
More informationOAB Treatment Guidelines
OAB Treatment Guidelines This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. It is part of the activity Overcoming
More informationSupplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI
Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI Authors: Tatyana A. Shamliyan, MD, MS Senior Director, Evidence-Based Medicine Quality Assurance Elsevier 1600 JFK Blvd,
More informationOveractive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION MIRABEGRON (Myrbetriq Astellas Pharma Canada Inc.) Indication: Overactive Bladder Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mirabegron be listed
More informationUrinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationOveractive Bladder: Identifying Patients at Risk, Implementing New Strategies
Overactive Bladder: Identifying Patients at Risk, Implementing New Learning Objectives Identify patients with OAB risk factors in order to proactively initiate a discussion about bladder symptoms and establish
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationDrugs for Overactive Bladder (OAB)
ril 2014 Drugs for Overactive Bladder (OAB) FINAL CONSOLIDATED COMPREHENSIVE RESEARCH PLAN July 2015 FINAL COMPREHENSIVE RESEARCH PLAN 2 A. Introduction The objective of the drug class review on drugs
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationDrugs for the overactive bladder: are there differences in persistence and compliance?
Editorial Drugs for the overactive bladder: are there differences in persistence and compliance? Karl-Erik Andersson 1,2 1 Institute for Regenerative Medicine, Wake Forest University School of Medicine,
More informationOveractive Bladder. Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan
Overactive Bladder Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan Speaker Disclosure I have nothing to disclose. 2 Learning Objectives Define OAB Identify
More informationDrug Class Review on Overactive Bladder Drugs
Drug Class Review on Overactive Bladder Drugs Preliminary Scan Report #1 February 2014 Last Summary Review (June 2013) The Agency for Healthcare Research and Quality has not yet seen or approved this report
More informationPriorities Forum Statement GUIDANCE
Priorities Forum Statement Number 61 Subject The management of female incontinence Date of decision May 2016 Date refreshed May 2017 Date of review May 2019 Introduction: GUIDANCE Urinary incontinence
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationInnovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
More informationResults The Authors. BJU Int 2017; 120:
Functional Urology Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study) Sender Herschorn*, Christopher
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION PROPIVERINE HYDROCHLORIDE (Mictoryl/Mictoryl Pediatric Duchesnay Inc.) Indication: Overactive bladder This document was originally issued on April
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationMirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year
bs_bs_banner International Journal of Urology (2014) 21, 960 967 doi: 10.1111/iju.12568 Review Article Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationPhiladelphia College of Osteopathic Medicine. Victoria J. Kopec Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Treatment With OnabotulinumtoxinA
More informationKathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA
Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Disclosures Advisory Board and/or Speaker Allergan Medtronic Astellas AUA Guidelines
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationPosterior Tibial Nerve Stimulation
Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)
More informationTreatment for Overactive Bladder
ril 2014 Treatment for Overactive Bladder Stakeholder Review STAKEHOLDER REVIEW 2 GENERAL Comment: ODPRN should consider more prominently identifying one of the key limitations in their assessment and
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationPresentation Goals 4/14/2015. Pharmacology for Urinary Incontinence in Women. Medications Review anti muscarinic medications Focus on newer meds
Presentation Goals Pharmacology for Urinary Incontinence in Women Medications Review anti muscarinic medications Focus on newer meds Introduce beta adrenergic medications Current Concepts in Drug Therapy
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationOveractive bladder. Information for patients from Urogynaecology
Overactive bladder Information for patients from Urogynaecology An overactive bladder (OAB) is a very common problem. It can cause distressing symptoms that are difficult to control. These can include
More informationClinical Policy: Posterior Tibial Nerve Stimulation for Voiding Dysfunction Reference Number: CP.MP.133
Clinical Policy: Reference Number: CP.MP.133 Effective Date: 10/16 Last Review Date: 10/16 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationManagement of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital
Management of Urinary Incontinence in Older Women Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital Epidemiology Causes Investigation Treatment Conclusion Elderly Women High prevalence
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationOveractive Bladder in Clinical Practice
Overactive Bladder in Clinical Practice Alan J. Wein Christopher Chapple Overactive Bladder in Clinical Practice Authors Alan J. Wein Division of Urology University of Pennsylvania Health System Philadelphia
More informationLong-term persistence with mirabegron in a real-world clinical setting
International Journal of Urology (2018) 25, 501--506 doi: 10.1111/iju.13558 Original Article: Clinical Investigation Long-term persistence with in a real-world clinical setting Naoki Wada, Masaki Watanabe,
More informationUrinary incontinence in women
Urinary incontinence in women Lauren N Wood, 1 Jennifer T Anger 2 1 Cedars-Sinai Medical Center, Department of Surgery, Division of Urology, Los Angeles, CA, USA 2 Urologic Reconstruction, Urodynamics,
More informationOveractive Bladder. Learning Objectives
Learning Objectives Describe neurophysiology of urinary storage and voiding and alterations that occur with pathology Define Overactive Bladder (OAB) and benign prostatic enlargement (BPE) and their impacts
More informationTHE OVER-ACTIVE BLADDER (OAB)
THE OVER-ACTIVE BLADDER (OAB) Passage of urine is caused by the bladder muscle contracting coordinated with the relaxation of the sphincter muscles, which is controlled by higher centers in the central
More informationSELF CARE IN URINARY INCONTINENCE
O P I N I O N SelfCare 2011;2(6):160-166 Advancing the study&understanding of self-care JULIAN SPINKS General Practitioner, Medway Primary Care Trust ABSTRACT Urinary incontinence and its associated urinary
More informationThe impact of Mirabegron on sexual function in women with idiopathic overactive bladder
Gubbiotti et al. BMC Urology (2019) 19:7 https://doi.org/10.1186/s12894-019-0438-8 RESEARCH ARTICLE Open Access The impact of Mirabegron on sexual function in women with idiopathic overactive bladder Marilena
More informationAdvanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa
Advanced Care for Female Overactive Bladder & Urinary Incontinence Department of Urology Kaiser Permanente Santa Rosa Goals Participants will: Review normal urinary tract anatomy and function Understand
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationOVERACTIVE BLADDER (OAB)
OVERACTIVE BLADDER (OAB) Ms Taryn Hallam Alana Health Care for Women Women s Health Training Associates OVERACTIVE BLADDER The most misdiagnosed and misunderstood of all the urinary disorders. Problem???
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationRational Pharmacotherapy for LUTS in Older People. Dr William Gibson MBChB MRCP
Rational Pharmacotherapy for LUTS in Older People Dr William Gibson MBChB MRCP Frailty Frailty = state of increased vulnerability resulting from agingassociated decline in reserve and function NOT synonymous
More information25-Feb-16 MANAGEMENT OF URINARY INCONTINENCE IN WOMEN.
Female Urinary Incontinence: GP resources MANAGEMENT OF URINARY INCONTINENCE IN WOMEN Dr Marcus Carey 20 February 2016 www.thewomens.org.au Clinical Practice Guidelines GP management of female urinary
More informationHow to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina
Reviews How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina Mikolaj Przydacz A F, Tomasz Golabek A,E,F, Piotr Chlosta A,E,F Department of Urology, Jagiellonian
More informationThe Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis
European Urology European Urology 48 (2005) 5 26 ReviewöOveractive Bladder The Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis Christopher Chapple a, *,
More informationAdditional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
Original Article - Female Urology Investig Clin Urol Posted online 217.6.27 Posted online 217.6.27 pissn 2466-493 eissn 2466-54X Additional low-dose antimuscarinics can improve overactive bladder symptoms
More informationOveractive bladder can result from one or more of the following causes:
Overactive bladder can affect people of any age; however, it is more common in older people. Effective treatments are available and seeing your doctor for symptoms of overactive bladder often results in
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationIntroduction. EAPEN RS, RADOMSKI SB. Gender differences in overactive bladder. Can J Urol 2016;23(Suppl 1):2-9.
Renu S. Eapen, MD, Sidney B. Radomski, MD Division of Urology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada EAPEN RS, RADOMSKI SB. Gender differences in overactive bladder.
More informationMultiple Sclerosis. Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
Queen Square Uro-neurology course, London, UK 20 th -21 st October 2016 Multiple Sclerosis Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
More informationPossible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic Patients
Med. J. Cairo Univ., Vol. 84, No. 1, March: 85-90, 2016 www.medicaljournalofcairouniversity.net Possible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic
More informationDee E. Fenner, M.D. Chair and Furlong Professor of Women s Health Dept. of Obstetrics and Gynecology University of Michigan.
Management of Overactive Bladder Dee E. Fenner, M.D. Chair and Furlong Professor of Women s Health Dept. of Obstetrics and Gynecology University of Michigan deef@umich.edu Disclosures NONE Objectives Review
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta290
Mirabegron for treating symptoms of overactive bladder Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta290 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPRE-OPERATIVE URODYNAMIC
PRE-OPERATIVE URODYNAMIC STUDIES: IS THERE VALUE IN PREDICTING POST-OPERATIVE STRESS URINARY INCONTINENCE IN WOMEN UNDERGOING PROLAPSE SURGERY? Dr K Janse van Rensburg Dr JA van Rensburg INTRODUCTION POP
More informationSecond-line Treatment for OAB
Patient Information English 35 Second-line Treatment for OAB The underlined terms are listed in the glossary. Sometimes the drugs your doctor prescribed do not improve your overactive symptoms (OAB). In
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 BETMIGA 25 mg, prolonged-release tablet B/30 (CIP: 34 009 273 182-5 2) BETMIGA 50 mg, prolonged-release
More informationUrinary Incontinence: What Can You Do to Improve Control? Learning Objectives
Urinary Incontinence: What Can You Do to Improve Control? Nicole J. Brandt, PharmD, MBA, CGP, BCPP, FASCP Professor, Geriatric Pharmacotherapy, Pharmacy Practice and Science UMB School of Pharmacy Director,
More informationBEST PRACTICE ADVOCACY CENTRE NEW ZEALAND SCOPE. Urinary incontinence in women: the management of urinary incontinence in women
BEST PRACTICE ADVOCACY CENTRE NEW ZEALAND SCOPE 1 Guideline title Urinary incontinence in women: the management of urinary incontinence in women 2 Guideline Contextualisation This is a contextualisation
More informationUK Consensus on Bladder Management in MS
Continence Care Forum Annual Conference UK Consensus on Bladder Management in MS Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Association of British Neurologists
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationParkinson s Disease and Multiple System Atrophy
Parkinson s Disease and Multiple System Atrophy Jalesh N. Panicker MD, FRCP Department of Uro-Neurology National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology Queen Square, London
More informationAccording to the INDICATIONS AND USAGE section of its FDA-approved product labeling (PI):
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Karen L. Walles, M.S. Assistant Director, Regulatory Affairs 3
More informationThe International Continence Society
REPORTS Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Adults Richard G. Roberts, MD, JD; Alan D. Garely, MD; and Tamara Bavendam, MD Abstract This article evaluates
More informationIs There a Best Drug for Overactive Bladder in a Patient with Dementia?
Is There a Best Drug for Overactive Bladder in a Patient with Dementia? Todd Semla, MS, Pharm.D., BCPS, FCCP, AGSF National PBM Clinical Pharmacy Program Manager Mental Health & Geriatrics U.S. Department
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationDiagnosis and Treatment of Urinary Incontinence. Urinary Incontinence
Diagnosis and Treatment of Urinary Incontinence Leslee L. Subak, MD Professor Obstetrics, Gynecology & RS Epidemiology, Urology University of California, San Francisco Urinary Incontinence Common - 25%
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Assessment and investigation of urinary incontinence in women bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated
More informationDr. Melissa Kagarise, PA C
Dr. Melissa Kagarise, PA C This program has been supported by an educational grant from Pfizer Pharmaceuticals PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of
More informationORIGINAL CLINICAL ARTICLE
Received: 20 January 2017 Accepted: 25 April 2017 DOI: 10.1002/nau.23315 ORIGINAL CLINICAL ARTICLE Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations
More informationEvaluation & Management of Overactive Bladder
Evaluation & Management of Overactive Bladder Disclosures/Conflict of Interest/Bias I have no financial relationship with any of the companies that produce the products I m about to discuss I have no conflicts
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationKingston Continence Service Clinical Audit on the Use of Video Urodynamic Studies
Kingston Continence Service Clinical Audit on the Use of Video Urodynamic Studies Lead researcher Dr. Anika Kibria Advanced Trainee in Geriatric Medicine A Video urodynamic Study (VUS) The technique combines
More informationUnknown Risks in Medicare Patients with Overactive Bladder
Unknown Risks in Medicare Patients with Overactive Bladder NMQF Summit April 24, 2017 Pamela Bradt, MD, MPH Executive Medical Director, Urology Medical Affairs, Americas Disclaimer This study was funded
More informationPelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS
Pelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS OhioHealth, Columbus Ohio Disclosures I have nothing to disclose Objectives Describe the role of a pelvic floor therapist in
More informationSubjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented Goals the Search for Value
european urology supplements 6 (2007) 438 443 available at www.sciencedirect.com journal homepage: www.europeanurology.com Subjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented
More informationDisclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.
Disclosures Geriatric Incontinence and Voiding Dysfunction None Shachi Tyagi MD, MS Assistant Professor Division of Geriatric Medicine University of Pittsburgh Medical Center UI: a Geriatric Syndrome Geriatric
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Text update pril 2014) J. Pannek (co-chair), B. Blok (co-chair), D. Castro-Diaz, G. del Popolo, J. Groen, G. Karsenty, T.M. Kessler, G. Kramer, M. Stöhrer Eur Urol 2009 Jul;56(1):81-8
More informationOveractive Bladder (OAB) Step Therapy Program Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Origination: 07/2013 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for brand name Overactive Bladder
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More information